Atlas Trials

Generalized Myasthenia Gravis

56 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Generalized Myasthenia Gravis

RecordFirmDate
Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis (NCT05403541)Immunovant Sciences GmbH2022-06-27
Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis (NCT05218096)Alexion Pharmaceuticals, Inc.2022-04-27
Study of ALXN1830 Administered Subcutaneously in Adults With Generalized Myasthenia Gravis (NCT04982289)Alexion Pharmaceuticals, Inc.2022-01-01
An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Patients With Generalized Myasthenia Gravis (NCT04980495)argenx2021-12-16
A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis (NCT05070858)Regeneron Pharmaceuticals2021-12-14
Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis (NCT04833894)argenx2021-10-26
A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis (NCT04963270)Hoffmann-La Roche2021-10-19
Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia Gravis (NCT04735432)argenx2021-02-05
Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis (NCT04225871)UCB Biopharma SRL2019-12-23
Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs) (NCT04202341)Alexion Pharmaceuticals, Inc.2019-12-02
A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis (NCT04124965)UCB Biopharma SRL2019-10-29
An Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients With Generalized Myasthenia Gravis (NCT03896295)Momenta Pharmaceuticals, Inc.2019-08-06
A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis (NCT03971422)UCB Biopharma SRL2019-06-03
Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis (NCT03920293)Alexion Pharmaceuticals, Inc.2019-03-12
A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness. (NCT03770403)argenx2019-03-01
An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness (NCT03669588)argenx2018-08-22
Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis (NCT03315130)Ra Pharmaceuticals2017-10-11
A Study Evaluating the Safety and Efficacy of Rituximab in Patients With Myasthenia Gravis (NCT02950155)Fredrik Piehl2016-10-16

Track Generalized Myasthenia Gravis automatically

Every clearance here is in the API, with alerts when new ones post.